

In the Claims:

Please cancel claims 1-5 and 13-41 and 43-49 without prejudice and replace with new claims 54-67 as follows:

~~53~~  
54. A fusion protein comprising an antigen or antigenic portion thereof, and a stress protein or a portion of the amino acid sequence of the stress protein, wherein the stress protein or portion thereof is able to induce a cell mediated cytolytic immune response against the antigen.

~~54~~  
55. The fusion protein of claim ~~54~~<sup>53</sup> wherein the antigen is selected from the group consisting of a viral antigen, a tumor associated antigen and an allergen.

~~55~~  
56. The fusion protein of claim ~~54~~<sup>53</sup> wherein the antigen is an antigen of the influenza virus.

~~56~~  
57. The fusion protein of claim ~~56~~<sup>55</sup> wherein the antigen of the influenza virus is selected from the group consisting of hemagglutinin, nucleoprotein, neuraminidase, M1, M2, PB1, PB2, PA and a combination thereof.

~~57~~  
58. The fusion protein of claim ~~54~~<sup>53</sup> wherein the fusion protein is selected from the group consisting of pET65MP/NP-B and pET65M/NP-D.

~~58~~  
59. The fusion protein of claim ~~54~~<sup>53</sup> wherein the antigen includes a cytolytic T cell epitope.

~~59~~  
60. The fusion protein of claim ~~54~~<sup>53</sup> wherein the antigen is selected from the group consisting of MAGE1, MAGE3, BAGE, GAGE, Tyrosinase, MART-1, gp100, pg75, MUM-1, HER2/neu, MUC-1, human papilloma virus proteins E6 and E7, GnT-V, beta-catenin, CDK4 and p15.

<sup>60</sup>  
~~61~~. The fusion protein of claim <sup>53</sup>~~54~~ wherein the stress protein is a bacterial stress protein.

<sup>61</sup>  
~~62~~. The fusion protein of claim <sup>60</sup>~~61~~ wherein the stress protein is a mycobacterial stress protein.

9 <sup>62</sup>  
~~63~~. The fusion protein of any one of claims <sup>53-61</sup>~~54-62~~ in combination with a pharmaceutically acceptable excipient, carrier, diluent or vehicle.

<sup>63</sup>  
~~64~~. A method of inducing a cell mediated cytolytic immune response against an antigen, comprising administering to a vertebrate in an amount effective to induce the immune response a fusion protein according to claim <sup>53</sup>~~54~~.

<sup>64</sup>  
~~65~~. The method of claim <sup>63</sup>~~64~~ wherein the fusion protein is in combination with a pharmaceutically acceptable excipient, carrier, diluent or vehicle.

<sup>65</sup>  
~~66~~. The method of claim <sup>63</sup>~~64~~ with the fusion protein of any one of claims <sup>54-61</sup>~~58-62~~.

<sup>66</sup>  
~~67~~. The method of claim <sup>65</sup>~~66~~ wherein the fusion protein is in combination with a pharmaceutically acceptable excipient, carrier, diluent or vehicle. —

P  
Co  
?